Safety, pharmacokinetics and efficacy of SCT200, an anti-EGFR monoclonal antibody in patients with wild-type KRAS/NRAS/BRAF metastatic colorectal cancer: a phase I dose-escalation and dose-expansion study

BACKGROUND: An over-expression of the epidermal growth factor receptor (EGFR) has been observed in colorectal cancer and is associated with aggressive disease and poor prognosis. SCT200 is a newly developed recombinant, fully humanized, anti-EGFR monoclonal antibody. This study aimed to evaluate its...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Wen, Han, Xiaohong, Yang, Lin, Song, Yuanyuan, Xie, Liangzhi, Gai, Wenlin, Wang, Yan, Shi, Yuankai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9617324/
https://www.ncbi.nlm.nih.gov/pubmed/36307775
http://dx.doi.org/10.1186/s12885-022-10147-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9617324/
https://www.ncbi.nlm.nih.gov/pubmed/36307775
http://dx.doi.org/10.1186/s12885-022-10147-9

Ejemplares similares